Stockscreener 앱 받기
17.99
4.21%
-0.79
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Aug Chart Watch: Whats the outlook for Denali Therapeutics Incs sectorAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Aug Patterns: Can Denali Therapeutics Inc withstand a market correctionMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
FOMO Trade: What makes FTRE stock attractive todayInflation Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com
Earnings Recap: Is BranchOut Food Inc a strong growth stockAnalyst Upgrade & AI Powered Market Trend Analysis - baoquankhu1.vn
Bear Alert: Will Denali Therapeutics Inc benefit from government policy2025 Market Overview & Fast Entry High Yield Stock Tips - baoquankhu1.vn
DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies - TradingView — Track All Markets
Denali Therapeutics unveils portfolio goals for 2026, stock up - MSN
Market Outlook: Is Denali Therapeutics Inc a turnaround storyStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential - DirectorsTalk Interviews
Rate Hike: Can Denali Therapeutics Inc scale operations efficientlyQuarterly Investment Review & Stepwise Trade Signal Implementation - baoquankhu1.vn
Have Denali Therapeutics Insiders Been Selling Stock? - simplywall.st
Why (DNLI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is Denali Therapeutics Inc. stock a good choice for value investors2025 Technical Patterns & Daily Volume Surge Trade Alerts - Улправда
What insider trading reveals about Denali Therapeutics Inc. stockRecession Risk & AI Powered Market Trend Analysis - Улправда
Investment Recap: Is Denali Therapeutics Inc stock recession proof2025 Top Gainers & Precise Buy Zone Identification - moha.gov.vn
DNLI Stock Price, Forecast & Analysis | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - Chartmill
Why analysts upgrade Denali Therapeutics Inc. stockQuarterly Trade Report & Low Drawdown Momentum Trade Ideas - Улправда
What RSI levels show for Denali Therapeutics Inc. (4DN) stockJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - Улправда
Ryan Watts Sells 35,198 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Sells Shares - TradingView — Track All Markets
Is Denali Therapeutics Inc. stock recession proofJuly 2025 Final Week & AI Powered Buy and Sell Recommendations - Улправда
Will Denali Therapeutics Inc. stock reach all time highs in 2025Quarterly Market Summary & Long-Term Growth Plans - Улправда
What risks investors should watch in Denali Therapeutics Inc. stockStochastic Oscillator Alerts & Outstanding Profit Investment - Улправда
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance
The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance
Performance Recap: Will Denali Therapeutics Inc. stock reach all time highs in 20252025 EndofYear Setup & Risk Managed Investment Entry Signals - Bộ Nội Vụ
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - sharewise.com
Will Denali Therapeutics Inc. stock see insider buyingMarket Depth Overview & Unlock Patterns Humans Can’t See - Улправда
Denali Therapeutics outlines key milestones for 2026 By Investing.com - Investing.com Nigeria
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential - Investing.com South Africa
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flows2026 world cup usa national team round of 32 young talents transition play winner prediction expert opinion - ulpravda.ru
Denali Prepares For Key Clinical And Regulatory Milestones - Nasdaq
Denali Therapeutics announces key anticipated milestones and priorities for 2026 - MarketScreener
Denali Therapeutics outlines key milestones for 2026 - Investing.com
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision - TipRanks
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome - The Manila Times
Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets
Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan
Denali Therapeutics sets 2026 priorities ahead of Tividenofusp decision - MSN
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Denali Therapeutics Earnings Notes - Trefis
Smart Money: Is Denali Therapeutics Inc stock recession proofM&A Rumor & Daily Technical Stock Forecast Reports - moha.gov.vn
Hunter Syndrome Treatment Market is expected to reach US$ - openPR.com
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential By Investing.com - Investing.com Nigeria
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial - Investing.com Nigeria
Understanding Momentum Shifts in (DNLI) - Stock Traders Daily
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence - Investing.com Nigeria
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence By Investing.com - Investing.com South Africa
4.73%
0.92%
자본화:
|
볼륨(24시간):